



Moxifloxacin 400 mg Injectable

The Issue: All NH supply of moxifloxacin 400 mg ready-to-use (RTU) injectable bags expired on April 30th, 2022 and replacement stock is not currently available to order. An estimated resupply date is unknown at this time. This is a relatively low use item in NH, but there will be a supply gap of unknown duration.

Anticipated Availability: undetermined at this time

Clinical Use: broad-spectrum antibiotic (respiratory fluoroquinolone)

Practice Implications:

- Clinicians should be aware of this shortage and potential alternatives.
- Oral moxifloxacin should be used whenever clinically appropriate as it has very high oral bioavailability.
- Levofloxacin remains available as an alternative injectable respiratory fluoroquinolone; however, this may also soon be in short supply and should be reserved for use when absolutely necessary (i.e. empiric treatment for severe community acquired pneumonia in combination with ceftriaxone when a macrolide is not appropriate).
- Clinicians can review NH-specific antimicrobial treatment guidelines on the [Firstline app](#) and/or discuss therapeutic alternatives with their local pharmacist(s).

Potential Alternatives*:

- Moxifloxacin 400 mg oral tablets
- Levofloxacin 5 mg/mL X 100 mL and 150 mL RTU injectable bags

May 2, 2022 For the information of physicians, nurses, and pharmacists. PLEASE POST	Drug Shortage	✓	For further information contact: Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	Drug Discontinuation		
	Medication Change		
	Best Practice		

*Alternatives are provided for clinician information and may not be appropriate for all clinical situations. The information provided does not replace clinical judgment.